Abstract

Background: Hepatitis C Virus (HCV) is the most common blood-borne infection in the U.S., affecting at least 4 million individuals. In CHC, providers and patients monitor disease status by liver function studies. While providers rely on liver biopsy as the gold standard, patients track alanine aminotransferase levels (ALT). Unfortunately, ALT is not a useful marker of disease progression in CHC.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call